Drug Type Biosimilar, Monoclonal antibody |
Synonyms Rituximab Biosimilar (BioXpress Therapeutics SA), BXT 2336, BXT-2336 + [1] |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Granulomatosis With Polyangiitis | Preclinical | Switzerland | 13 Mar 2024 | |
| Lymphoid Leukemia | Preclinical | Switzerland | 13 Mar 2024 | |
| Microscopic Polyangiitis | Preclinical | Switzerland | 13 Mar 2024 | |
| Non-Hodgkin's lymphoma refractory | Preclinical | Switzerland | 13 Mar 2024 | |
| Pemphigus | Preclinical | Switzerland | 13 Mar 2024 | |
| Rheumatoid Arthritis | Preclinical | Switzerland | 13 Mar 2024 |






